ArticleVaccine2025
Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- What Antibody Repertoires See: Structural and Immunogenetic Insights Into Influenza A Virus Hemagglutinin Recognition.Immunological reviews · 2026Review
- Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets.Vaccines · 2026Article
- Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.Vaccine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Current seasonal influenza virus vaccines are inefficient at inducing protective immune responses against drifted seasonal or emerging pandemic influenza viruses. A strategy to elicit more broadly cross-protective immune responses is to target conserved epitopes of the influenza virus, and the neuraminidase (NA) glycoprotein and the stalk domain of the hemagglutinin (HA) have become prime vaccine candidates. Sequential immunization with chimeric HA (cHA) antigens in which the immunodominant HA head domain has been replaced by HA head domains of exotic subtypes is able to re-focus the immune response to the HA stalk. Similarly, vaccination with recombinant NA (rNA) protein induces robust anti-NA responses. In this study, we show that sequential immunization with group 2 chimeric HA (cHA) inactivated split vaccines in combination with rN2 NA protein (rNA-N2-MPP) elicits superior immune responses and protection against a heterologous influenza virus in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.